Cyclerion Updates Corporate Progress
April 10, 2020 07:00 ET
|
Cyclerion Therapeutics, Inc.
– Closed enrollment for olinciguat Phase 2 STRONG SCD study for sickle cell disease; topline data readout expected Q3 2020 – – Closed enrollment for IW-6463 translational pharmacology...
Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases
January 13, 2020 07:00 ET
|
Cyclerion Therapeutics, Inc.
– Results in 110 subjects demonstrate favorable safety, CNS pharmacokinetics, and evidence of target engagement – – Study underway in elderly subjects to further assess cerebral blood flow and...
Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference
November 27, 2019 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...
Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy
October 30, 2019 07:31 ET
|
Cyclerion Therapeutics, Inc.
– Study did not reach statistical significance on primary endpoint – – Positive trends on primary and secondary endpoints indicate profile that merits further investigation – – Company intends to...
Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF)
October 30, 2019 07:30 ET
|
Cyclerion Therapeutics, Inc.
– Study in HFpEF patients did not meet primary endpoint; company discontinuing development of praliciguat in HFpEF – – Conference call to be held at 8:30 a.m. ET today – CAMBRIDGE, Mass., Oct. ...
Cyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings
October 08, 2019 08:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for...
Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17
September 10, 2019 08:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...
Cyclerion Therapeutics Reports Second Quarter 2019 Financial Results and Progress on Four Clinical Studies with Data Readouts Anticipated in the Next 12 Months
August 12, 2019 08:00 ET
|
Cyclerion Therapeutics, Inc.
– Two praliciguat Phase 2 studies for diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF) on track for data readouts in Q4 2019 – – Phase 2 study of olinciguat in sickle...
Cyclerion Therapeutics to Present Preclinical Data on its Clinical-Stage sGC Stimulators for Neurodegenerative and Cardiometabolic Diseases at the 9th International Conference on cGMP
June 11, 2019 08:30 ET
|
Cyclerion Therapeutics, Inc.
– Series of preclinical studies provide further rationale for study of IW-6463 as a potential treatment for neurodegenerative diseases – – Preclinical data provide insights into...
Cyclerion Therapeutics to Present Data on its Sickle Cell Disease Program at Upcoming Medical and Scientific Meetings
June 04, 2019 08:30 ET
|
Cyclerion Therapeutics, Inc.
– In preclinical study, treatment with company’s investigational sGC stimulator olinciguat was associated with improved blood flow and reduced inflammation in a model of sickle cell disease – – New...